Development of a peptide ELISA for the diagnosis of Equine arteritis virus.

The researchers have developed a method to quickly and effectively detect Equine arteritis virus (EAV) using a peptide-based ELISA test.

Development of the Peptide-Based ELISA

• The study involves the creation of a peptide-based indirect Enzyme-Linked Immunosorbent Assay (ELISA). This is a test that measures the reaction of antibodies in a sample, in this case, horse blood serum, to specific viral proteins or peptides.
• Here, the researchers designed and synthesized two peptides. These peptides act as antigens – substances that induce an immune response in the body and generate the production of antibodies.
• The two selected peptides represented epitope C of protein GP5 and fragment E of protein M from the Equine arteritis virus (EAV).

Testing and Evaluation

• The peptides were tested both separately and in combination as antigens using 92 serum samples extracted during the 2010 Equine viral arteritis outbreak. These samples had previously been analyzed using a different method – virus neutralization.
• The best resolution was achieved when using the peptide that replicated the GP5 protein.
• Moreover, the examination of inter- and intraplate variability indicated that the test developed is robust, implying that it produced reliable and consistent results.

Significance and Applications

• The study’s findings show that this newly developed peptide-based ELISA can serve as an efficient alternative to virus neutralization tests, which are currently recommended by the World Organization for Animal Health (OIE).
• Advantages of the new method are that it can be standardized across different laboratories, allowing for consistency in testing.
• Additionally, the new test allows for quicker diagnosis of EAV-negative horses, providing faster results, which could lead to a speedier treatment for infected animals.
• Lastly, the developed ELISA can also be employed for routine surveillance in large horse populations, thus aiding in preventing potential EAV outbreaks in the future.